SAB Biotherapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2019
Period Ending	Jun '25 Jun 5, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2019
Market Capitalization	17	35	63	30	340	-	Upgrade
Market Cap Growth	-69.84%	-44.79%	113.36%	-91.25%	-	-	Upgrade
Enterprise Value	11	9	66	27	336	-	Upgrade
Last Close Price	1.87	3.79	6.88	5.90	78.10	-	Upgrade
PS Ratio	45.84	26.48	28.33	1.24	5.58	-	Upgrade
PB Ratio	0.81	1.35	1.11	0.96	8.81	-	Upgrade
P/TBV Ratio	0.80	1.35	1.11	0.96	8.81	-	Upgrade
P/OCF Ratio	-	-	-	-	170.89	-	Upgrade
EV/Sales Ratio	29.07	6.91	29.32	1.14	5.51	-	Upgrade
Debt / Equity Ratio	0.32	0.18	0.10	0.19	0.22	0.21	Upgrade
Debt / EBITDA Ratio	-	-	-	-	-	0.38	Upgrade
Asset Turnover	0.01	0.02	0.03	0.36	0.88	1.48	Upgrade
Quick Ratio	1.33	2.61	5.23	1.37	1.56	3.00	Upgrade
Current Ratio	1.69	2.98	5.45	1.47	1.90	3.12	Upgrade
Return on Equity (ROE)	-92.35%	-81.92%	-95.51%	-53.85%	-44.21%	86.15%	Upgrade
Return on Assets (ROA)	-48.28%	-41.86%	-35.30%	-27.37%	-12.16%	34.47%	Upgrade
Return on Capital (ROIC)	-61.14%	-57.16%	-47.50%	-43.00%	-17.77%	41.14%	Upgrade
Return on Capital Employed (ROCE)	-	-	-	-	-	45.20%	Upgrade
Earnings Yield	-201.04%	-97.39%	-66.52%	-63.04%	-5.05%	-	Upgrade
FCF Yield	-185.03%	-98.89%	-39.91%	-86.20%	-2.64%	-	Upgrade
Buyback Yield / Dilution	-41.12%	-67.74%	-26.86%	-59.20%	-1.21%	23.30%	Upgrade

Updated Nov 6, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q